March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Visual Loss in Orbitofacial Neurofibromatosis Type 1
Author Affiliations & Notes
  • Thomas M. Bosley
    Ophthalmology, Ophthalmology,
    King Saud University, Riyadh, Saudi Arabia
  • Darren T. Oystreck
    Ophthalmology, Ophthalmology,
    King Saud University, Riyadh, Saudi Arabia
  • Jose Morales
    Ophthalmology, Ophthalmology,
    King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Imtiaz Chaudhry
    Ophthalmology, Ophthalmology,
    King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Ibrahim A. Alorainy
    Radiology, Diagnostic Imaging,
    King Saud University, Riyadh, Saudi Arabia
  • Sahar M. Elkhamary
    Radiology, Diagnostic Imaging,
    King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Footnotes
    Commercial Relationships  Thomas M. Bosley, None; Darren T. Oystreck, None; Jose Morales, None; Imtiaz Chaudhry, None; Ibrahim A. Alorainy, None; Sahar M. Elkhamary, None
  • Footnotes
    Support  King Abdulaziz City for Science and Technology [Project AT-29-31]
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1559. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thomas M. Bosley, Darren T. Oystreck, Jose Morales, Imtiaz Chaudhry, Ibrahim A. Alorainy, Sahar M. Elkhamary; Visual Loss in Orbitofacial Neurofibromatosis Type 1. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1559.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : On occasion, neurofibromas in neurofibromatosis type 1 may be present on the lid, brow, or face of an infant or child, a circumstance commonly referred to as orbitofacial neurofibromatosis (OFNF). In this study we evaluate the causes and extent of visual loss in a group of patients with OFNF.

Methods: : Retrospective medical record review and re-examination of selected patients from one institution, including assessment of visual acuity and identification of underlying etiology of reduced vision.

Results: : Fifty patients with unilateral OFNF (23 males: 27 females; ages 4 to 48 at last visit) and five with bilateral OFNF (2 males: 3 females; ages 15 to 43 years) had adequate information available to assess afferent visual functioning. Nine (4 males: 5 females; ages 4 to 28 years) patients had optic pathway glioma in addition to OFNF. Patients were followed as long as 27 years (mean 8.4 years). Thirty-nine patients (71% of total) had visual acuity of 20/60 or worse on the side of OFNF involvement (or the side of worse OFNF involvement in patients with bilateral disease). One or more causes of amblyopia were present in 29 of these patients, while 19 had organic disease of the eye (e.g., glaucoma and/or retinal detachment) or the afferent system (e.g., optic pathway glioma), and 12 had correctable refractive errors.

Conclusions: : Visual loss in this OFNF cohort was common, typically profound, and usually multifactorial. Unfortunately, some causes of visual loss (including congenital glaucoma with buphthalmos and retinal detachment; disconjugate gaze due in part to distorted skull development causing strabismic amblyopia; and OPG) were difficult to treat adequately and tended to cause progressive, profound visual loss. Therefore, careful observation should be made during the period of visual immaturity for possible causes of amblyopia that might be treatable such as refractive changes, occlusion of the visual axis, or congenital glaucoma. As affected individuals get older, physicians must be vigilant for the progression of optic nerve disease due to glaucoma or optic pathway glioma and to the possibility that vision might be improved by refraction.

Keywords: genetics • amblyopia • optic nerve 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×